Following the discovery of the anti-VEGF chemotherapeutic bevacizumab (Avastin, Genentech, South San Francisco, CA, USA) that was first used in colon cancer, the first effective use of intravitreal anti-VEGF in nAMD was subsequently undertaken, representing a revolution for retinal therapy at the time [3, 4]. The gene discussed is VEGFA; the disease is malignant colon neoplasm.